ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Xenotransplantation-focused eGenesis has secured $38 million in its first round of financing. The biotech firm plans to use the gene-editing technology CRISPR to engineer pig cells to grow human-transplantable cells, tissues, and organs. eGenesis was founded by renowned Harvard Medical School geneticist George Church and his former postdoctoral researcher Luhan Yang, who developed a way to use CRISPR to get rid of pathogenic factors in pig cells. Yang now serves as eGenesis’s chief scientific officer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter